These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 7714410

  • 1. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.
    Yanni JM, Stephens DJ, Parnell DW, Spellman JM.
    J Ocul Pharmacol; 1994; 10(4):665-75. PubMed ID: 7714410
    [Abstract] [Full Text] [Related]

  • 2. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
    Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA.
    J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
    [Abstract] [Full Text] [Related]

  • 3. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA, Leahy C, Krenzer KL.
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.
    Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM.
    Arch Ophthalmol; 1999 May; 117(5):643-7. PubMed ID: 10326962
    [Abstract] [Full Text] [Related]

  • 5. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
    Kida T, Fujii A, Sakai O, Iemura M, Atsumi I, Wada T, Sakaki H.
    Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
    [Abstract] [Full Text] [Related]

  • 6. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies.
    Sharif NA, Su SX, Yanni JM.
    J Ocul Pharmacol; 1994 Jul; 10(4):653-64. PubMed ID: 7714409
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis.
    Discepola M, Deschenes J, Abelson M.
    Acta Ophthalmol Scand Suppl; 1999 Jul; (228):43-6. PubMed ID: 10337432
    [Abstract] [Full Text] [Related]

  • 8. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
    Schoch C.
    Ocul Immunol Inflamm; 2005 Feb; 13(1):39-44. PubMed ID: 15804768
    [Abstract] [Full Text] [Related]

  • 9. Effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimida zole difumarate (KB-2413), a new antiallergic, on chemical mediators.
    Fukuda T, Morimoto Y, Iemura R, Kawashima T, Tsukamoto G, Ito K.
    Arzneimittelforschung; 1984 Feb; 34(7):801-5. PubMed ID: 6149754
    [Abstract] [Full Text] [Related]

  • 10. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
    Verin P, Easty DL, Secchi A, Ciprandi G, Partouche P, Nemeth-Wasmer G, Brancato R, Harrisberg CJ, Estivin-Ebrardt C, Coster DJ, Apel AJ, Coroneo MT, Knorr M, Carmichael TR, Kent-Smith BT, Abrantes P, Leonardi A, Cerqueti PM, Modorati G, Martinez M.
    Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
    [Abstract] [Full Text] [Related]

  • 11. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J, Duval D, Prouteau M, Voltz C, Berry CN, Lloyd KG, Scatton B.
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
    Sanchis-Merino ME, Montero JA, Ruiz-Moreno JM, Rodriguez AE, Pastor S.
    Exp Eye Res; 2008 May; 86(5):791-7. PubMed ID: 18378229
    [Abstract] [Full Text] [Related]

  • 13. Antiallergic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidaz ole difumarate (KB-2413).
    Fukuda T, Saito T, Tajima S, Shimohara K, Ito K.
    Arzneimittelforschung; 1984 May; 34(7):805-10. PubMed ID: 6208915
    [Abstract] [Full Text] [Related]

  • 14. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group.
    Secchi A, Leonardi A, Discepola M, Deschenes J, Abelson MB.
    Acta Ophthalmol Scand Suppl; 2000 May; (230):48-51. PubMed ID: 11057351
    [Abstract] [Full Text] [Related]

  • 15. Effects of E-4716, a new antihistaminic with antiallergic properties, on chemical mediators induction of immunologic reactions.
    Gutiérrez B, Dordal A, Fort M, Galicia J, Farré AJ.
    Methods Find Exp Clin Pharmacol; 1996 May; 18(6):397-406. PubMed ID: 8892269
    [Abstract] [Full Text] [Related]

  • 16. Application of histamine-induced conjunctivitis to the assessment of a topical antihistamine, levocabastine.
    Feinberg G, Stokes TC.
    Int Arch Allergy Appl Immunol; 1987 May; 82(3-4):537-8. PubMed ID: 2883131
    [Abstract] [Full Text] [Related]

  • 17. The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis.
    Kato M, Kurose T, Oda T, Miyaji S.
    J Ocul Pharmacol Ther; 2003 Aug; 19(4):315-24. PubMed ID: 12964956
    [Abstract] [Full Text] [Related]

  • 18. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis.
    Orfeo V, Vardaro A, Lena P, Mensitieri I, Tracey M, De Marco R.
    Eur J Ophthalmol; 2002 Aug; 12(4):262-6. PubMed ID: 12219994
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate.
    el-Shazly AE, Masuyama K, Samejima Y, Eura M, Ishikawa T.
    Immunopharmacol Immunotoxicol; 1996 Nov; 18(4):587-95. PubMed ID: 8933171
    [Abstract] [Full Text] [Related]

  • 20. Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: inhibition by the histamine H1 antagonist emedastine.
    Weimer LK, Gamache DA, Yanni JM.
    Int Arch Allergy Immunol; 1998 Apr; 115(4):288-93. PubMed ID: 9566351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.